DPPE-PEG350
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


DPPE-PEG350
Description :
DPPE-PEG350 is a CD1d-dependent lipid antagonist thus blocking the ERK phosphorylation pathway in iNKT cells[1][2]. DPPE-PEG350 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles.Product Name Alternative :
16:0 PEG350 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol) -350] (ammonium)UNSPSC :
12352211Target :
CD1; LiposomeType :
Biochemical Assay ReagentsRelated Pathways :
Immunology/Inflammation; Metabolic Enzyme/ProteaseApplications :
Metabolism-protein/nucleotide metabolismField of Research :
OthersAssay Protocol :
https://www.medchemexpress.com/16-0-peg350-pe.htmlSolubility :
10 mM in DMSOSmiles :
O=C(NCCOP(O)(OC[C@@H](COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)=O)OCCOC.N.[n]Molecular Formula :
(C2H4O) nC39H76NO10P.H3NMolecular Weight :
350 (Average)References & Citations :
[1]Xiao H, et al. Regulation of microglia polarization via mannose receptor-mediated delivery of siRNA by ligand-functionalized DoGo LNP. RSC Adv. 2021 Oct 4;11 (52) :32549-32558.|[2]Sommonte F, et al. In-House Innovative "Diamond Shaped" 3D Printed Microfluidic Devices for Lysozyme-Loaded Liposomes. Pharmaceutics. 2022 Nov 16;14 (11) :2484.|[3]Li Y, Kanellakis P, Hosseini H, Cao A, Deswaerte V, Tipping P, Toh BH, Bobik A, Kyaw T. A CD1d-dependent lipid antagonist to NKT cells ameliorates atherosclerosis in ApoE-/- mice by reducing lesion necrosis and inflammation. Cardiovasc Res. 2016 Feb 1;109 (2) :305-17. |[4]Lombardi V, Stock P, Singh AK, Kerzerho J, Yang W, Sullivan BA, Li X, Shiratsuchi T, Hnatiuk NE, Howell AR, Yu KO, Porcelli SA, Tsuji M, Kronenberg M, Wilson SB, Akbari O. A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol. 2010 Feb 15;184 (4) :2107-15.Shipping Conditions :
Room temperatureScientific Category :
Reference compound1Clinical Information :
No Development ReportedIsoform :
CD1bCAS Number :
[474922-84-4]

